Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“The MSK retrospective experience with ADC sequencing (T-DXd -> SG or viceversa) for MBC.
Among 85 patients included, 75% had a worse PFS with the second ADC, irrespective of the sequence. Confirms multiple reports of cross resistance between topo1 ADCs.”
Title: Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan
Authors: Nicholas Mai, Miriam M. Klar Lieberman, Emanuela Ferraro, Maria Bromberg, Yuan Chen, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Elaine M. Walsh, Joshua Z. Drago
You can read the Full Article on JCO Precision Oncology
More posts featuring Paolo Tarantino.